Core Points - The company has completed the change registration of its "Drug Production License" and obtained the new license from the Hunan Provincial Drug Administration [1] - The validity of the "Drug Production License" has been extended to October 16, 2030 [1][3] - The company has made several changes to its production lines and added new products to its production scope [1][3] License Change Details - The license validity has been extended from December 3, 2025, to October 16, 2030 [1] - The production address for the raw material drug (Ibandronate) has been updated to "Raw Material Drug Workshop (Workshop 101) B Area and E Area" [1] - The company has added the production of "Raw Material Drug (Benidipine Hydrochloride)" at the same production address [1] - The company has commissioned Tian Di Heng Yi Pharmaceutical Co., Ltd. to produce "Yuan Qi Bone Pain Tincture" with a validity until October 16, 2030 [1] - Additional commissioned production information has been included for two products: "Flurbiprofen Gel Patch" and "Compound Glycyrrhizin Tablets" [1] Production Scope and Impact - The production scope includes various forms of drugs such as powder injections, tablets, hard capsules, and raw materials [3] - The changes in the "Drug Production License" will not affect the company's existing production structure and will maintain stable production capacity [3] - The new license is not expected to have a significant impact on the company's current performance [3]

Core Viewpoint - Fangsheng Pharmaceutical has recently completed the change registration of its "Drug Production License" and obtained the new license issued by the Hunan Provincial Drug Administration [2] Company Summary - Fangsheng Pharmaceutical announced the completion of the change registration for its "Drug Production License" [2] - The company has received the updated "Drug Production License" from the Hunan Provincial Drug Administration [2]

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-087 湖南方盛制药股份有限公司 关于公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）近期完成 了《药品生产许可证》的变更登记并取得了湖南省药品监督管理 局核发的《药品生产许可证》。现将相关情况公告如下： 一、《药品生产许可证》的变更内容 1、《药品生产许可证》有效期由2025年12月3日延长至2030 年10月16日； 2、生产地址3湖南望城经济开发区铜官镇循环经济工业基地 内黄龙路368号的原料药（依折麦布）生产车间生产线由"原料 药车间（101车间）A区与E区依折麦布生产线"（原名：原料药 I车间依折麦布生产线）变更为"原料药车间（101车间）B区与E 区依折麦布生产线"； 3、在生产地址3湖南望城经济开发区铜官镇循环经济工业基 地内黄龙路368号增加"原料药（盐酸贝尼地平）"生产范 ...

Core Viewpoint - The company has received a renewed drug production license from the Hunan Provincial Drug Administration, which includes several changes to its production capabilities and license validity [1] Summary by Relevant Sections - **License Renewal**: The drug production license has been extended until October 16, 2030 [1] - **Production Changes**: Modifications include changes to the production line for the raw material drug Ezetimibe and the addition of the raw material drug Benidipine to the production scope [1] - **Operational Stability**: The changes will not affect the company's existing production structure, ensuring stable production capacity [1] - **License Number**: The new license number is 湘20150028 [1]

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, specifically recommending companies like Zhaoli Pharmaceutical and Fangsheng Pharmaceutical as undervalued high-dividend Chinese medicine stocks [1]. Core Insights - The report highlights that the Chinese medicine sector is characterized by strong cash flow and low debt ratios, making it capable of high dividend payouts. This sector is less affected by international political dynamics, making it a viable defensive strategy in a volatile market [16][17]. - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > Chinese medicine > medical devices > pharmacies [10][12]. Summary by Sections 1. Significant Excess Returns in Pharmaceutical Stocks - The A-share pharmaceutical index has shown a year-to-date increase of 18.85%, with a weekly decline of 2.48%. The Chinese medicine sector saw a slight increase of 0.38%, while other sectors like medical services and medical devices experienced declines [4][9]. 2. High Dividend Yield in Chinese Medicine Sector - The report emphasizes the attractiveness of high dividend yields in the Chinese medicine sector, with companies like Zhaoli Pharmaceutical expected to have a dividend yield of 4.1% in 2025, and Fangsheng Pharmaceutical at 3.1% [17][18]. 3. R&D Progress and Company Dynamics - Recent developments include the approval of innovative drugs and clinical trials by various companies, indicating ongoing advancements in the sector [4][12]. 4. Industry and Regulatory Insights - The report provides insights into the regulatory landscape affecting the pharmaceutical industry, noting that the impact of tariff wars on the sector is limited [4]. 5. Market Review - The report tracks the performance of various pharmaceutical sub-sectors, noting that the Chinese medicine sector has outperformed others in recent weeks [4][9].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603998 证券简称：方盛制药 公告编号：2025-086 湖南方盛制药股份有限公司 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年10月17日（星期五）至10月23日（星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱fs88997135@126.com、603998@fangsheng.com.cn进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 湖南方盛制药股份有限公司（以下简称"公司"）将于2025年10月24日发布公司2025年第三季度报告，为 便于广大投资者更全面深入地了解公司2025年第三季度经营成果、财务状况，公司计划于2025年10月24 日（星期五）09:00-10:00举行2025年第三季度业绩说明会，就投资者关心的问题进行交流。 关于召开2025年第三季度业绩说明会的公告 一、说明会类型 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-086 湖南方盛制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 24 日（星期五）09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 17 日（星期五）至 10 月 23 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 fs88997135@126.com、603998@fangsheng.com.cn 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 湖南方盛制药股份有限公司（以下简称"公司 ...

Group 1: Drug Development Announcement - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., received the Clinical Trial Approval Notice for the drug RuLuGoli Tablets from the National Medical Products Administration [1][2] - RuLuGoli Tablets are a GnRH receptor antagonist intended for the treatment of advanced prostate cancer [2] - The cumulative R&D investment for this drug project is approximately 3.89 million yuan (unaudited) [3] Group 2: Market Situation - The original drug for RuLuGoli Tablets was developed by Takeda Pharmaceutical Company and was first approved for sale in Japan on January 8, 2019 [4] - As of the announcement date, RuLuGoli Tablets have not yet been launched in China, and no original or generic products have been approved for sale [4] - In 2023, the global sales amount for RuLuGoli Tablets reached approximately $29.96 million, with a year-on-year growth rate of 58.6% [4] Group 3: Approval Process - After receiving the Clinical Trial Approval Notice, the company must conduct and complete clinical trials and submit the application for product listing according to the relevant regulations [5] Group 4: Share Pledge Announcement - The controlling shareholder, Zhang Qinghua, completed the pledge of 35 million shares (7.97% of the total share capital) on October 15, 2025 [8][9] - As of the announcement date, Zhang Qinghua directly holds 156,019,500 shares, accounting for 35.53% of the total shares [8] - The pledged shares do not exceed 80% of the total shares held, indicating that the overall pledge risk is controllable [8][12]

证券日报网讯 10月15日晚间，方盛制药发布公告称，近日，公司全资子公司广东方盛健盟药业有限公 司化药仿制药研发项目瑞卢戈利片收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。 （编辑 楚丽君） ...

证券日报网讯 10月15日晚间，方盛制药发布公告称，公司控股股东暨实际控制人张庆华先生办理完成 了3，500万股股份质押手续。 （文章来源：证券日报） ...